Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - ENTERED INTO EXCLUSIVE COMMERCIAL COOPERATION AGREEMENT2023.01.03
-
VOLUNTARY ANNOUNCEMENT - ENTERED INTO EXCLUSIVE PROMOTION AGREEMENT2022.12.29
-
VOLUNTARY ANNOUNCEMENT - COMPLETION OF PATIENT ENROLLMENT IN PHASE III CLINICAL TRIAL OF RECOMBINANT HUMAN COAGULATION FACTOR VIIA FOR INJECTION2022.12.09
-
VOLUNTARY ANNOUNCEMENT - IND APPLICATION OF INNOVATIVE MEDICINE “TCC1727” FILED WITH AND ACCEPTED BY FDA2022.12.09
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 20222022.12.01
-
VOLUNTARY DISCLOSURE - 2022 THIRD QUARTER UPDATE2022.11.02
-
RESIGNATION OF EXECUTIVE DIRECTOR2022.11.02
-
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS2022.11.02